Olipudase Alfa — supply status, manufacturers & alternatives

Olipudase Alfa

—

🇦🇺 AUST R 394103 · Sanofi-Aventis Australia Pty Ltd

In supply · Australia

Xenpozyme

In supply · 🇦🇺 Australia · short in🇫🇷 FR

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Olipudase Alfa
Brand names	Xenpozyme
Therapeutic category	Auto-created by Agence nationale de sécurité du médicament — Disponibilité scraper

Controlled substance	No

Marketing-authorisation holders	Sanofi-Aventis Australia Pty Ltd

Registrations on file	2

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Shortage status by regulator official notices

🇫🇷

France

ANSM · 11h ago

Medium

Verified timeline regulator events

🇫🇷 17 Mar 2026

medium reported

Sources official regulators

🇫🇷

ANSM

verified 11h ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders2 registrations · 1 MA holder

Product	Strength	Form	Market	MA holder	Status
XENPOZYME olipudase alfa	20mg	—	🇦🇺 AU	Sanofi-Aventis Australia Pty Ltd	Active
XENPOZYME olipudase alfa	4mg	—	🇦🇺 AU	Sanofi-Aventis Australia Pty Ltd	Active

Mederti Drug Report

Generated 4 July 2026 · Australia market · 1 regulatory source

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.